References
- Brittain H. Perspective on polymorphism. Pharm. Tech 1994; 18: 50–52
- Ebian A. R., Moustafa M. A., Khalil S. A., Motawi M. M. Effect of additives on the kinetics of interconversion of sulphamethoxydiazine crystal forms. J. Pharm. Pharmac 1973; 25: 13–20
- Frederick K. J. Performance and problems of pharmaceutical suspensions. J. Pharm. Sci 1961; 50: 531–535
- Higuchi T. Some physical chemical aspects of suspension formulation. J. Am. Pharm. Ass., Sci. Ed 1958; 47: 657–660
- Ke X., Ping Q., Shi H. Study on mechanism of formation of betamethasone acetate different crystal forms. Journal of China Pharmaceutical University 2003; 34: 430–432
- Ke X., Ping Q., Shi H. Interconversion studies of betamethasone acetate polymorphs. Drug Development and Industrial Pharmacy 2005; 31: 813–818
- Nurnberg V. E., Seiller E. Darstellung polymorpher modificationer des batemethasoneacetats. Pharm Ind 1988; 50: 1085–1090
- Simonelli A. P., Mehta S. C., Higuchi W. I. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J. Pharm. Sci 1979; 59: 633–637
- Singhal D., Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Advanced Drug Delivery Reviews 2004; 56: 335–347
- Snider D. A., Addicks W., Owens W. Polymorphism in genetic drug product development. Advanced Drug Delivery Reviews 2004; 56: 391–395